Physician profile
Steven Naids
NPI 1487917530
$52,269.38
in general payments reported to CMS, 2019-2025
37 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $3,868 · 2021: $7,865 · 2022: $15K · 2023: $1,140 · 2024: $1,018 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.27 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14,270.37 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $13,679.72 | 2019-2022 | |
| Allergan, INC. | $11,271.94 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $4,032.22 | 2019 | |
| Abbvie INC. | $1,757.97 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,194.26 | 2019-2023 | |
| Alcon Vision LLC | $497.97 | 2019-2025 | Eysuvis, Tryptyr, Clareon |
| Thea Pharma INC. | $490.68 | 2024-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $470.72 | 2020-2025 | Tecnis Iol, Tecnis Iol |
| New World Medical,INC. | $452.61 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $449.36 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $416.02 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $357.28 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $356.80 | 2020-2025 | Idosetr |
| Shire North American Group INC | $352.73 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $266.49 | 2019-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $246.39 | 2019-2021 | |
| Akorn, INC. | $235.26 | 2019-2020 | |
| Harrow Eye, LLC | $211.21 | 2024-2025 | Vevye, Iheezo |
| Sun Pharmaceutical Industries INC. | $184.73 | 2019-2025 | |
| Horizon Therapeutics Plc | $146.84 | 2022 | |
| Rayner Intraocular Lenses Limited | $143.93 | 2023 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Optos, INC. | $117.12 | 2020 | |
| Ocular Therapeutix, INC. | $104.63 | 2023-2025 | Dextenza |
| Akorn Operating Company LLC | $97.01 | 2021 | |
| Ani Pharmaceuticals, INC. | $71.61 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $65.00 | 2021-2022 | |
| Astellas Pharma US INC | $62.51 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $57.10 | 2024-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $53.54 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $39.62 | 2021 | |
| Lensar, INC. | $27.35 | 2023 | Lensar Laser System |
| Rxsight INC | $25.08 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Eyepoint US, INC. | $21.23 | 2019 | |
| Amgen INC. | $16.03 | 2025 | Tepezza |
| Biotissue Holdings INC. | $14.87 | 2019 | |
| Quidel Corporation | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Naids listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.